269 related articles for article (PubMed ID: 34777337)
1. Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis.
Kashani N; Kelland EE; Vajdi B; Anderson LM; Gilmore W; Lund BT
Front Immunol; 2021; 12():706278. PubMed ID: 34777337
[TBL] [Abstract][Full Text] [Related]
2. Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
Gilmore W; Lund BT; Li P; Levy AM; Kelland EE; Akbari O; Groshen S; Cen SY; Pelletier D; Weiner LP; Javed A; Dunn JE; Traboulsee AL
J Neuroinflammation; 2020 Jun; 17(1):189. PubMed ID: 32539719
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment.
Haas J; Würthwein C; Korporal-Kuhnke M; Viehoever A; Jarius S; Ruck T; Pfeuffer S; Meuth SG; Wildemann B
Front Immunol; 2019; 10():1204. PubMed ID: 31214176
[TBL] [Abstract][Full Text] [Related]
4. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis.
Syed YY
Drugs; 2021 Jan; 81(1):157-168. PubMed ID: 33367970
[TBL] [Abstract][Full Text] [Related]
6. Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study.
Palmeri S; Ponzano M; Ivaldi F; Signori A; Lapucci C; Casella V; Ferrò MT; Vigo T; Inglese M; Mancardi GL; Uccelli A; Laroni A
CNS Drugs; 2022 Jan; 36(1):83-96. PubMed ID: 34894339
[TBL] [Abstract][Full Text] [Related]
7. Restoration of regulatory B cell deficiency following alemtuzumab therapy in patients with relapsing multiple sclerosis.
Kim Y; Kim G; Shin HJ; Hyun JW; Kim SH; Lee E; Kim HJ
J Neuroinflammation; 2018 Oct; 15(1):300. PubMed ID: 30373595
[TBL] [Abstract][Full Text] [Related]
8. Effects of Alemtuzumab on (Auto)antigen-Specific Immune Responses.
Hilger C; Riedhammer C; Orsó E; Weissert R
Front Immunol; 2020; 11():563645. PubMed ID: 33133074
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis.
Li Z; Richards S; Surks HK; Jacobs A; Panzara MA
Clin Exp Immunol; 2018 Dec; 194(3):295-314. PubMed ID: 30144037
[TBL] [Abstract][Full Text] [Related]
10. Immune reconstitution following alemtuzumab therapy is characterized by exhausted T cells, increased regulatory control of proinflammatory T cells and reduced B cell control.
von Essen MR; Chow HH; Holm Hansen R; Buhelt S; Sellebjerg F
Front Immunol; 2023; 14():1249201. PubMed ID: 37744364
[TBL] [Abstract][Full Text] [Related]
11. Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab.
Wiendl H; Carraro M; Comi G; Izquierdo G; Kim HJ; Sharrack B; Tornatore C; Daizadeh N; Chung L; Jacobs AK; Hogan RJ; Wychowski LV; Van Wijmeersch B;
Neurol Neuroimmunol Neuroinflamm; 2020 Jan; 7(1):. PubMed ID: 31662412
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
Hersh CM; Cohen JA
Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab for the treatment of multiple sclerosis.
Evan JR; Bozkurt SB; Thomas NC; Bagnato F
Expert Opin Biol Ther; 2018 Mar; 18(3):323-334. PubMed ID: 29309202
[TBL] [Abstract][Full Text] [Related]
14. Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis.
Akgün K; Blankenburg J; Marggraf M; Haase R; Ziemssen T
Front Immunol; 2020; 11():56. PubMed ID: 32082320
[No Abstract] [Full Text] [Related]
15. Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.
González-Oria MC; Márquez-Coello M; Girón-Ortega JA; Argente J; Moya M; Girón-González JA
J Neuroimmune Pharmacol; 2019 Sep; 14(3):413-422. PubMed ID: 30649665
[TBL] [Abstract][Full Text] [Related]
16. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
17. ALAIN01--Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.
Ruck T; Afzali AM; Lukat KF; Eveslage M; Gross CC; Pfeuffer S; Bittner S; Klotz L; Melzer N; Wiendl H; Meuth SG
BMC Neurol; 2016 Mar; 16():34. PubMed ID: 26966029
[TBL] [Abstract][Full Text] [Related]
18. The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies.
Baker D; Ali L; Saxena G; Pryce G; Jones M; Schmierer K; Giovannoni G; Gnanapavan S; Munger KC; Samkoff L; Goodman A; Kang AS
Front Immunol; 2020; 11():124. PubMed ID: 32117274
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.
Brown JW; Coles AJ
Drug Des Devel Ther; 2013; 7():131-8. PubMed ID: 23494602
[TBL] [Abstract][Full Text] [Related]
20. Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF.
Möhn N; Pfeuffer S; Ruck T; Gross CC; Skripuletz T; Klotz L; Wiendl H; Stangel M; Meuth SG
Neurol Neuroimmunol Neuroinflamm; 2020 Mar; 7(2):. PubMed ID: 31826986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
